Edition:
United States

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

2.20USD
23 Feb 2018
Change (% chg)

$-0.05 (-2.22%)
Prev Close
$2.25
Open
$2.26
Day's High
$2.26
Day's Low
$2.15
Volume
20,286
Avg. Vol
238,010
52-wk High
$6.06
52-wk Low
$1.25

Chart for

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 1.80
Market Cap(Mil.): $35.02
Shares Outstanding(Mil.): 16.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Celsion Corporation Provides Corporate Update And 2018 Outlook

* CELSION CORPORATION PROVIDES CORPORATE UPDATE AND 2018 OUTLOOK

Jan 18 2018

BRIEF-Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy

* CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER

Jan 04 2018

BRIEF-Celsion reports Q3 loss of $0.70/shr

* Celsion Corporation reports third quarter 2017 financial results and provides business update

Nov 14 2017

BRIEF-Celsion files immunotherapy clinical protocol for the evaluation of Gen-1

* Celsion files immunotherapy clinical protocol for the evaluation of Gen-1 to treat newly diagnosed ovarian cancer

Nov 13 2017

BRIEF-CELSION ANNOUNCES PRICING OF COMMON STOCK OFFERING

* CELSION CORPORATION ANNOUNCES PRICING OF UNDERWRITTEN OFFERING OF COMMON STOCK AND WARRANTS TO PURCHASE COMMON STOCK

Oct 27 2017

BRIEF-Celsion provides update on Thermodox in liver cancer study

* Celsion provides update on Thermodox® in the Phase III Optima study of primary liver cancer

Sep 27 2017

Earnings vs. Estimates